Aspirin Statins Or Both For The Reduction Of Thrombin Generation In Diabetic People (RATIONAL)
Despite formal recommendations, evidence of efficacy of aspirin in individuals with diabetes is scant and controversial. While the efficacy of aspirin versus placebo in patients with diabetes is currently under investigation in big randomized controlled trials, the putative additive effects of aspirin and statins in this population remain to be investigated. Moreover there are no data examining the pathophysiologic means by which aspirin with or without statins affects thrombosis in diabetic patients.
The aim of this trial is to evaluate the efficacy of low-dose aspirin (100 mg/daily), statins, both or neither for the reduction of thrombin generation. These preventive strategies will be evaluated on the top of the other strategies aimed at optimizing the care of diabetic patients in terms of metabolic control and control of the other cardiovascular risk factors.
|Diabetes Mellitus||Drug: Aspirin Drug: Atorvastatin Drug: Aspirin + Atorvastatin||Phase 4|
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Treatment
|Official Title:||Aspirin Statins Or Both For The Reduction Of Thrombin Generation In Diabetic People|
- Thrombin generation [ Time Frame: 8 weeks ]
- C-reactive protein [ Time Frame: 8 weeks ]
|Study Start Date:||March 2009|
|Study Completion Date:||October 2011|
|Primary Completion Date:||October 2011 (Final data collection date for primary outcome measure)|
|No Intervention: 1|
Aspirin 100 mg / day
100 mg / day for 8 weeks
Atorvastatin 40 mg / day
40 mg / day for 8 weeks
Aspirin 100 mg / day + Atorvastatin 40 mg / day
Drug: Aspirin + Atorvastatin
Aspirin 100 mg / day + Atorvastatin 40 mg / day for 8 weeks
Despite the very high cardiovascular risk profile, evidence of efficacy of aspirin in individuals with diabetes is scant.
The meta-analysis on the efficacy of antiplatelet therapy involving a total of about 5,000 diabetic subjects indicates a non significant reduction in the risk of major cardiovascular events of 7%, compared with a reduction of 25% documented in secondary prevention studies.
Diabetes could represent a special case of aspirin resistance, although no specific studies have, to our knowledge, fully explored this hypothesis. The poor platelet responsiveness to aspirin has been recently proposed as a possible explanation of the failure of antiplatelet therapy to prevent cardiovascular events. The reduction in the aspirin activity in some patients is indicated by the failure in adequately suppressing thromboxane-A2 synthesis, as documented by the presence of high levels of its urinary metabolites.
The substantial lack of clear evidence is reflected by the low use of this drug in clinical practice; in fact, only 10% of diabetic patients are treated with aspirin for the prevention of cardiovascular events.
On the other hand, statins provide a similar efficacy for the prevention of major cardiovascular events in populations with and without diabetes.
It has been recently shown that platelet response to aspirin is linearly reduced with increasing cholesterol plasma levels. The presence of dyslipidemia, particularly common among diabetic patients, could thus be at least partially responsible for a lower efficacy of aspirin in this population. The concomitant use of statins could thus restore the normal platelet sensitivity to aspirin by reducing cholesterol levels
One additional reason to hypothesize a positive effect of statins in improving platelet response to aspirin is related to their anti-inflammatory properties
While the efficacy of aspirin versus placebo in patients with diabetes is currently under investigation, the additive effects of aspirin and statins in this population remain to be investigated. This aspect is of particular interest in the light of the existing debate regarding the need of multiple interventions to reduce total cardiovascular risk.
Given these premises, it is important to evaluate the effectiveness of aspirin use in primary prevention of cardiovascular events in association with statins therapy when included in a strategy of global risk control.
The RATIONAL Study will evaluate whether the combined use of aspirin (100 mg d) and statins (Atorvastatin 40 mg daily) is superior to the use of these single agents for the reduction of thrombin generation in patients with diabetes and without previous cardiovascular events.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00793754
|Centro de Educación Médica e Investigaciones Clínicas (CEMIC)|
|Buenos Aires, Argentina|
|Principal Investigator:||Alejandro Macchia, MD||Fundacion GESICA|
|Principal Investigator:||Hernan Doval, MD||Fundacion GESICA|
|Principal Investigator:||Juan J Fuselli, MD||Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno|
|Principal Investigator:||Pablo D Comignani, MD||Hospital Aleman|